Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

NCT07521605 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Rectal Cancer Patients

Interventions

RADIATION: Short-Course Radiotherapy
DRUG: Liposomal Irinotecan (nal-IRI)
DRUG: Capecitabine
DRUG: Camrelizumab

Sponsor

Guangdong Provincial People's Hospital